Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
4.118
-0.312 (-7.05%)
At close: Nov 4, 2026, 4:00 PM EST
3.895
-0.223 (-5.41%)
After-hours: Nov 4, 2026, 7:30 PM EST
Revelation Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Gemini, a novel anti-inflammatory therapy, is advancing to a pivotal adaptive phase II/III trial for acute kidney injury, with FDA support for a composite endpoint and efficient study design. Strong clinical and preclinical data support broad potential, and cash runway extends into Q1 2027.